ANALYSIS OF COVID-19 TREATMENT APPROACHES Podgaina M. V., Ivakhnenko K. National University of Pharmacy, Kharkiv, Ukraine economica@nuph.edu.ua

Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment. Older people, and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness.

The best way to prevent and slow down transmission is to be well informed about the COVID-19 virus, the disease it causes and how it spreads. Protect yourself and others from infection by washing your hands or using an alcohol based rub frequently and not touching your face.

The COVID-19 virus spreads primarily through droplets of saliva or discharge from the nose when an infected person coughs or sneezes, so it's important that you also practice respiratory etiquette (for example, by coughing into a flexed elbow).

A number of investigational agents and drugs that are approved for other indications are currently being studied in clinical trials for the treatment of COVID-19 and associated complications. Data from randomized controlled trials, prospective and retrospective observational cohorts, and case series studies are rapidly emerging. The COVID-19 Treatment Guidelines Panel (the Panel) continues to review the most recent clinical data to provide up-to-date treatment recommendations to clinicians who are caring for patients with COVID-19.

From updated of Octovber 9, 2020, WHO recommends following medicines for Therapeutic Management of Patients with COVID-19 hospitalized and requires supplemental oxygen: remdesevir and dexametazon in different dosage depends on patient's state.

In Ukraine The Order of the Ministry of Health of Ukraine on March 28, 2020 \mathbb{N} 722 approved the standards of medical care "coronavirus disease (COVID-19)" updated the treatment protocol COVID-19. The new version of the protocol "Provision of medical care for the treatment of coronavirus disease (COVID-19)" was signed by the Minister of Health on September 17. The protocol was developed by specialists of the Ministry and the top qualified specialists in the field of healthcare. In general, the protocol fully includes approaches to drug therapy and oxygen support for coronavirus infection treatment. The protocol provides the use of symptomatic therapy (antipyretics) for light form of disease and the addition of low molecular weight heparins for the moderate form of disease, further addition of glucocorticosteroids in severe COVID-19's form in adults. Pharmacotherapy of pediatric patients includes the drug remdesevir from the beginning of therapy.

Our future investigations will include the pharmaceutical domestic market and pricing policy of the indicated medicines and calculation of costs for COVID-19's pharmakotherapy.